Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function by Zajac, Allan J. et al.
 
2205
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/98/12/2205/09 $2.00
Volume 188, Number 12, December 21, 1998 2205–2213
http://www.jem.org
 
Viral Immune Evasion Due to Persistence of
Activated T Cells Without Effector Function
 
By Allan J. Zajac, Joseph N. Blattman, Kaja Murali-Krishna, 
David J.D. Sourdive, M. Suresh, John D. Altman, and Raﬁ Ahmed
 
From the Emory Vaccine Center and Department of Microbiology and Immunology, Emory University 
School of Medicine, Atlanta, Georgia 30322
 
Summary
 
We examined the regulation of virus-specific CD8 T cell responses during chronic lympho-
cytic choriomeningitis virus (LCMV) infection of mice. Our study shows that within the same
persistently infected host, different mechanisms can operate to silence antiviral T cell responses;
CD8 T cells specific to one dominant viral epitope were deleted, whereas CD8 T cells re-
sponding to another dominant epitope persisted indefinitely. These virus-specific CD8 T cells
expressed activation markers (CD69
 
hi
 
, CD44
 
hi
 
, CD62L
 
lo
 
) and proliferated in vivo but were un-
able to elaborate any antiviral effector functions. This unresponsive phenotype was more pro-
nounced under conditions of CD4 T cell deficiency, highlighting the importance of CD8–
CD4 T cell collaboration in controlling persistent infections. Importantly, in the presence of
CD4 T cell help, adequate CD8 effector activity was maintained and the chronic viral infection
eventually resolved. The persistence of activated virus-specific CD8 T cells without effector
function reveals a novel mechanism for silencing antiviral immune responses and also offers
new possibilities for enhancing CD8 T cell immunity in chronically infected hosts.
Key words: cytotoxic T cells • unresponsiveness • chronic infections • CD4 T cells • major 
histocompatibility complex tetramers
 
C
 
D8 T cells eliminate viruses by killing infected cells
and by producing antiviral cytokines such as IFN-
 
g
 
(1–6). These T cells are of importance in chronic viral in-
fections and several studies have documented a role for
CD8 CTLs in controlling persistent infections of humans
with hepatitis B virus, Epstein-Barr virus, and cytomega-
lovirus (6–11). Also, there is now convincing evidence that
decreased CD8 T cell responses are associated with high vi-
ral burden and poor prognosis in HIV-infected individuals
(12–17). In such chronic infections, continuous presence of
functional CD8 T cells is essential to keep the virus in
check, and loss of CD8 T cell responses can lead to resur-
gence of virus. One condition that results in loss of CD8
responses is CD4 deficiency. Studies with murine models
of chronic viral infections have shown that CD4 T cells are
essential for maintaining CD8 CTL responses (18–20), and
in humans there is a correlation between the decline of
CD4 T cells and loss of HIV-specific CD8 T cell responses
during the progression of AIDS (21). However, it is not
known whether loss of CD8 T cell function under these
conditions is due to deletion of virus-specific CD8 T cells
or due to induction of anergy (unresponsiveness) in these
cells (13, 19, 22–24). It is important to distinguish between
these two mechanisms of silencing immune responses be-
cause this information is critical for designing therapeutic
strategies for enhancing T cell responses in persistently in-
fected individuals.
To address this issue and to investigate the role of CD4
T cells in regulating CD8 T cell responses, we have studied
infection of normal (
 
1
 
/
 
1
 
) and CD4 knockout (
 
2/2
 
)
mice with lymphocytic choriomeningitis virus (LCMV).
 
1
 
We have used MHC class I tetramers complexed with de-
fined viral epitopes to directly visualize antigen-specific
CD8 T cells and have measured antiviral T cell effector
functions using cytotoxicity and cytokine production assays
(25–27). This approach allows us to simultaneously moni-
tor the physical presence and functional activity of virus-
specific CD8 T cells. Moreover, the use of MHC class I
 
1
 
Abbreviations used in this paper: 
 
1/1 
 
mice, C57BL/6J mice; BrdU,
5-bromo-2
 
9
 
-deoxyuridine; CD4
 
2/2
 
, CD4-deficient; GP, glycoprotein;
LCMV,  lymphocytic choriomeningitis virus; NP, nucleoprotein.
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tetramers to identify antigen-specific T cells obviates the
need to use TCR transgenic cells. Viral infections induce
polyclonal antiviral T cell responses directed towards multi-
ple epitopes; therefore, studies with monoclonal TCR
transgenic cells may not mimic the regulation of polyclonal
virus–specific CD8 T cells (4, 10, 22, 28). In this study we
show that antiviral CD8 T cell responses are silenced dur-
ing chronic infections by different mechanisms depending
upon the viral epitope. CD8 T cells specific for the LCMV
nucleoprotein (NP)396–404 epitope were deleted, whereas
CD8 T cells specific to another dominant epitope, glyco-
protein (GP)33–41, persisted indefinitely. These LCMV
GP33–41-specific CD8 T cells expressed activation mark-
ers (CD69
 
hi
 
, CD44
 
hi
 
, and CD62L
 
lo
 
) but were unable to ei-
ther kill virus infected cells or release antiviral cytokines
such as IFN-
 
g
 
. These “unresponsive” cells were found pre-
dominantly under conditions of CD4 T cell deficiency,
documenting the importance of CD4 T cells in maintain-
ing CD8 T cell responses during chronic viral infections.
 
Materials and Methods
 
Mice and Virus.
 
C57BL/6J (
 
1
 
/
 
1
 
) and C57BL/6-
 
Cd4
 
tm1Mak
 
CD4-deficient (CD4
 
2/2
 
) mice (29) were obtained from The
Jackson Laboratory (Bar Harbor, ME). Animals were housed in
American Association for Accreditation of Laboratory Animal
Care (AAALAC) accredited facilities and experiments were per-
formed in accordance with institutional guidelines. Mice were
used at 6–8 wk of age.
For acute infections mice were infected by intraperitoneal in-
jection of 2 
 
3 
 
10
 
5
 
 PFU of LCMV Armstrong. To establish
chronic LCMV, infection mice were infected by intravenous in-
jection of 2 
 
3 
 
10
 
6
 
 PFU of the LCMV variant t1b or clone 13. In
all cases viral titers were determined by plaque assay, as previously
described (30). In certain experiments mice were transiently de-
pleted of CD4
 
1
 
 cells by intraperitoneal injection of partially puri-
fied anti-CD4 monoclonal antibody GK1.5 (19). The antibody
was administered 1 d before and 3 d after virus infection and re-
sulted in a 
 
.
 
95% reduction in the number of splenic CD4 T cells.
 
Secondary CTL Assays and Limiting Dilution Analysis.
 
Second-
ary bulk CTL assays were performed as previously described (19).
In brief, single cell suspensions of splenocytes (8 
 
3 
 
10
 
6
 
 cells) were
restimulated in vitro with 2 
 
3 
 
10
 
6
 
 splenocytes from congenital
LCMV carrier mice. After 5 d of culture, virus-specific CTL ac-
tivity was determined using standard 6-h 
 
51
 
Cr-release assays. Lim-
iting dilution analysis (LDA) was also performed as previously de-
scribed (31). In brief, graded doses of spleen cells from infected
mice were added to 96-well plates and cultured in the presence of
recombinant IL-2 (50 U/ml) together with irradiated splenocytes
from congenital LCMV carrier mice. After 8 d of culture, the
contents of each well were split and virus-specific CTL activity
was measured. For both secondary CTL and LDA, target cells for
cytotoxicity assays were either noninfected MC57 (H-2
 
b
 
) cells or
MC57 cells that had been infected 48 h previously with LCMV.
 
IFN-
 
g
 
 ELISPOT Assays.
 
IFN-
 
g
 
–producing spleen cells were
enumerated using IFN-
 
g
 
–specific ELISPOT assays (26). 96-well
filtration plates (Millipore Corp., Bedford, MA) were coated
overnight with 0.4 
 
m
 
g/well of purified anti–IFN-
 
g
 
. Coated plates
were washed twice with PBS to remove unbound antibody and
then blocked for 1–2 h with RPMI 1640 supplemented with 10%
FCS. Graded doses of responder cells were added to the wells fol-
 
lowed by 5 
 
3 
 
10
 
5
 
 irradiated (1,100 rad) syngeneic splenic feeder
cells. Recombinant IL-2 (50 U/ml final concentration) was
added to all wells. Cultures were either untreated or stimulated
with peptide epitopes (0.1 
 
m
 
g/ml final concentration) and the
volume was adjusted to 200 
 
m
 
l/well.
Cultures were incubated for 40 h at 37
 
8
 
C in 6% CO
 
2
 
. After
this period cells were removed by two washes with PBS and two
additional washes using PBS/0.05% (vol/vol) Tween 20. Each
well then received 0.4 
 
m
 
g biotinylated anti–IFN-
 
g
 
 antibody di-
luted in PBS/0.05% Tween 20/0.1% FCS. After overnight incu-
bation at 4
 
8
 
C, unbound secondary antibody was removed by
three washes with PBS/0.05% Tween 20. Horseradish peroxi-
dase–conjugated streptavidin was diluted 1:100 in PBS/0.05%
Tween 20/0.1% FCS and 100 
 
m
 
l of this solution was added to
each well. After 1 h at room temperature, plates were washed
three times with PBS. ELISPOTS were developed by the addi-
tion of 3-amino-9-ethyl-carbazole diluted in 0.1 M acetate
buffer, pH 5, containing H
 
2
 
O
 
2
 
. Reactions were allowed to pro-
ceed for 
 
z
 
10 min and were halted by extensive washing in water.
Plates were dried and spots were counted using a stereomicro-
scope with indirect illumination.
 
Intracellular Staining.
 
To enumerate the number of IFN-
 
g
 
–,
IL-2–, IL-4–, and IL-10–producing cells, intracellular cytokine
staining was performed as previously described (26). In brief, 10
 
6
 
freshly explanted splenocytes were cultured in flat-bottomed 96-
well plates. Cells were left untreated, stimulated with LCMV-
specific peptide epitopes (0.1 
 
m
 
g/ml), or treated with PMA (10
ng/ml) and ionomycin (500 ng/ml). In certain experiments the
cytokine production profile of an OVA-specific CD4
 
1
 
 Th2 cell
clone (provided by J. Kapp and A. Long, Emory University, At-
lanta, GA) was similarly analyzed. The OVA 323–339 peptide
was used to stimulate this cell line. In all cases cells were incu-
bated for 6 h at 37
 
8
 
C in 6% CO
 
2
 
. Brefeldin A was added for the
duration of the culture period to facilitate intracellular cytokine
accumulation. After this period cell surface staining was per-
formed, followed by intracellular cytokine staining using the
Cytofix/Cytoperm kit (PharMingen, San Diego, CA) in accor-
dance with the manufacturer’s recommendations. For intracellu-
lar cytokine staining, the antibodies used were anti–IFN-
 
g
 
 (clone
XMG1.2), anti–IL-2 (clone JES6-5H4), anti–IL-4 (clone 11B11),
and anti–IL-10 (clone JES5-16E3). All antibodies were purchased
from PharMingen.
 
Flow Cytometry and Tetramer Staining.
 
MHC class I (H-2D
 
b
 
)
tetramers complexed with either LCMV–GP33–41 or LCMV–
NP396–404 peptides were produced exactly as previously de-
scribed (25, 26). Biotinylated D
 
b
 
 peptide complexes were tetramer-
ized by the addition of allophycocyanin-conjugated streptavidin.
Freshly explanted splenocytes (10
 
6
 
) were stained in PBS/2%
(wt/vol) BSA/0.2% (wt/vol) NaN
 
3
 
 using fluorochrome conju-
gated antibodies and MHC class I tetramers. The antibodies used
were anti-CD8 (clone 53-6.7), anti-CD44 (clone IM7), anti-
CD62L (clone MEL-14), and anti-CD69 (clone H1.2F3). All anti-
bodies were purchased from PharMingen. After staining, cells were
fixed in PBS/2% (wt/vol) paraformaldehyde, and events acquired
using a FACSCalibur
 
Ò
 
 flow cytometer (Becton Dickinson). Dead
cells were excluded on the basis of forward and side light scatter.
Data was analyzed using the computer program CELLQuest (Bec-
ton Dickinson).
 
BrdU Labeling and Staining.
 
The in vivo proliferation of LCMV-
specific CD8 T cells was assessed by administering 5-bromo-2
 
9
 
-
deoxyuridine (BrdU) (0.8 mg/ml) in drinking water for 8 d. After
this period splenocytes were isolated and stained with anti-CD8-
PE and D
 
b
 
(GP33–41) tetramers conjugated to allophycocyanin. 
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Figure 1. CD8 T cell effector
functions are lost during chronic in-
fection of CD42/2 mice. (A) Serum
virus titers were measured in 1/1
(d) and age-matched CD42/2 ( s)
mice at various times after infection
with LCMV-t1b. The limit of de-
tection is indicated by the dashed
line. (B) CTL activity of splenocytes
from 1/1 (j, h) or CD42/2 (r,
e) mice at 90 d after infection with
LCMV-t1b was measured after 5 d
restimulation in vitro. Target cells
were either uninfected (open symbols)
or LCMV infected (filled symbols).
(C) Limiting dilution analysis was
performed using splenocytes from either 1/1 (m) or CD42/2 (n) mice at 90 d after infection with LCMV-t1b. The frequency of LCMV-specific cells
per spleen is indicated in parentheses. (D) Virus-specific IFN-g secreting cells were enumerated using single cell ELISPOT assays. Splenocytes were isolated
from either 1/1 or CD42/2 mice at 90 d after inoculation with LCMV-t1b.
 
Samples were also stained for BrdU incorporation, using anti-
BrdU antibodies (Clone B44, Becton Dickinson) as previously
described (26, 32). Flow cytometry and data analysis were per-
formed as described above.
 
Results
 
CD8 T Cell Effector Functions Are Lost during Chronic Infec-
tion of CD4
 
2/2
 
 Mice.
 
Infection of adult 
 
1
 
/
 
1
 
 or CD4
 
2/2
 
mice with the Armstrong strain of LCMV results in an
acute infection (19, 29, 33). Both 
 
1
 
/
 
1
 
 and CD4
 
2/2
 
 mice
make potent LCMV-specific CD8 T cell responses and
clear the virus within 1 wk. However, infection with
LCMV variants that rapidly spread to many tissues
 
 
 
in vivo
leads to strikingly different outcomes in 
 
1
 
/
 
1
 
 and CD4
 
2/2
 
mice (18, 19). An example of this is shown in Fig. 1. Adult
 
1
 
/
 
1
 
 mice infected with LCMV variant t1b (19, 34) had
no detectable viremia after day 30 and virus was cleared
from most of their tissues within 2 mo, except for the kid-
neys that contained low levels (
 
z
 
10
 
3
 
 PFU/organ) of virus
for 
 
.1 yr. In contrast CD42/2 mice failed to clear the in-
fection and these mice contained high levels of virus in all
tissues tested; .106 PFU in spleen, lymph nodes, thymus,
liver, lung, brain, kidney, and salivary gland (Fig. 1 A, data
not shown). Virus-specific CD8 T cells, as measured by
their ability to kill infected cells and to secrete IFN-g, were
present in 1/1 mice but no functional CD8 T cell re-
sponses could be detected in CD42/2 mice. No LCMV-
specific CD8 T cell responses were present in chronically
infected CD42/2 mice either directly ex vivo or after re-
stimulation with virus in vitro. Data from mice analyzed at
day 90 after infection are shown in Fig. 1, B, C, and D.
Epitope-dependent T Cell Deletion and Functional Unrespon-
siveness during Chronic Infection. To determine if loss of
CD8 T cell responses in chronically infected CD42/2 mice
was due to peripheral deletion of virus-specific T cells or
due to functional unresponsiveness, MHC class I tetramers
complexed to immunodominant LCMV epitopes (GP33–
41 and NP396–404) were used to visualize antigen-specific
CD8 T cells (Fig. 2). Uninfected (naive) and LCMV im-
mune mice (i.e., mice that had undergone an acute LCMV
Armstrong infection) were included as negative and posi-
tive controls. No virus-specific CD8 T cells were detect-
able (frequency ,1/105) in naive mice (Fig. 2, A, E, and I),
whereas immune mice contained GP33- and NP396-spe-
cific CD8 T cells at frequencies of z2% (1/50 CD8 T
cells) and z5% (1/20 CD8 T cells), respectively (Fig. 2, B
Figure 2. T cell deletion and functional unresponsiveness are distinct
mechanisms for silencing antiviral immune responses. Naive 1/1 mice,
1/1 immune mice (161 d after LCMV Armstrong infection; 2 3 105
PFU, i.p.), and 1/1 or CD42/2 mice infected with LCMV-t1b (2 3 106
PFU, i.v.) 60 d previously were checked for the physical presence and
functional responsiveness of LCMV-specific CD8 T cells. (A–H) LCMV-
specific CD8 T cells were visualized using MHC class I tetramers com-
plexed to viral peptides. Cells were costained with anti-CD8–PE, anti-
CD44–FITC, and either Db(GP33–41) or Db(NP396–404) tetramers
conjugated to allophycocyanin. The histograms show gated CD8 lym-
phocytes, and the percentage of CD8 cells costaining with either
Db(GP33–41) or Db(NP396–404) are indicated in the corresponding up-
per right quadrant. Where not shown values are ,0.2%. (I–L) Numbers
of LCMV-specific IFN-g producing cells were enumerated using single-
cell cytokine ELISPOT assays. The number of splenocytes producing
IFN-g after stimulation with either GP33–41 (black bars) or NP396–404
peptides (hatched bars) are shown (6 SD).2208 Silencing CD8 T Cells during Chronic Viral Infection
and F). The tetramer binding cells in LCMV immune mice
were CD44hi, a marker for activated/memory T cells (35),
and all of these antigen-specific cells were fully functional;
z100% of these cells produced IFN-g after stimulation
with the appropriate peptides (Fig. 2 J). 1/1 mice that had
undergone a protracted (4–6 wk) LCMV-t1b infection ex-
hibited a selective deletion of NP396-specific CD8 T cells
(Fig. 2, C and G). These mice still contained GP33-specific
CD8 T cells (Fig. 2 C) at a frequency (1/50) comparable to
that seen in 1/1 Armstrong immune mice and, as in the
immune group, these GP33-specific CD8 T cells were
CD44hi and most of these cells were functional based on
IFN-g production (Fig. 2 K). Thus, 1/1 mice that were
infected for 4–6 wk and subsequently eliminated virus from
most of their tissues had lost their NP396-specific CD8 T
cell responses due to peripheral deletion of these cells but
still retained their GP33-specific responses. An interesting
variation of this phenotype was seen in chronically infected
CD42/2 mice. In these mice, similar to in 1/1 mice,
NP396-specific CD8 T cells were deleted (Fig. 2 H) and
GP33-specific CD8 T cells were present (Fig. 2 D), but in
striking contrast to 1/1 mice, nearly all (.98%) of these
cells were nonfunctional (Fig. 2 L). Although CD42/2 mice
contained as many GP33 tetramer binding cells as 1/1
mice, and these cells were also CD44hi, few if any of these
virus-specific CD8 T cells were able to secrete IFN-g or
kill LCMV-infected cells. Taken together, these results
show that the mechanism of peripheral tolerance during
chronic viral infections can vary depending upon the
epitope specificity of the T cells; in the case of NP396-spe-
cific CD8 T cells, silencing of the response was due to
physical deletion of the antigen-specific cells, whereas for
GP33-specific CD8 T cells, loss of function was due to un-
responsiveness. Most importantly, these data show that vi-
rus-specific T cells can persist during chronic viral infection
but these T cells are incapable of eliciting their normal ar-
ray of antiviral effector functions (i.e., cytotoxicity and
IFN-g production).
In certain conditions (36, 37), immune “deviation” can
occur, resulting in the synthesis of an alternative set of cy-
tokines by responding T cells. To address this possibility,
intracellular cytokine staining was performed. After 6 h
stimulation in vitro with GP33 peptide, freshly explanted
spleen cells from both LCMV-t1b–infected 1/1 mice and
CD42/2 mice failed to produced IL-2, IL-4, or IL-10 (data
not shown). Identical intracellular staining procedures de-
tected significant amounts of IL-4 and IL-10 after in vitro
stimulation of an OVA-specific CD4 Th2 cell clone. How-
ever, IFN-g was produced by spleen cells from LCMV-
t1b–infected 1/1 mice, but splenocytes isolated from sim-
ilarly infected CD42/2 mice did not produce detectable
levels of IFN-g. Thus, during chronic infection, GP33-
specific CD8 T cells do not exhibit an altered pattern of
cytokine production. Moreover, in the absence of CD4 T
cell help, these cells fail to elicit any detectable effector
functions and the viral infection is not resolved.
The kinetics of LCMV epitope–specific responses were
examined during the course of chronic infection to deter-
mine when NP396-specific CD8 T cells were deleted and
when GP33-specific cells became unresponsive (Fig. 3). In
both 1/1 and CD42/2 mice infected with LCMV clone
13 (30), NP396-specific CD8 T cells were deleted by day
50 after infection. After expansion and differentiation into
effectors during the first week after infection, NP396-spe-
cific CD8 T cells became progressively unresponsive and
were then deleted in the periphery. In striking contrast,
GP33-specific CD8 T cells persisted indefinitely. During
the initial phase of infection both groups of mice contained
a mixture of functional and nonfunctional GP33-specific
CD8 T cells. In 1/1 mice, a fraction (10–20%) of these T
cells remained functional and the LCMV infection was
eventually resolved (Fig. 3 A). However, in CD42/2 mice
all the GP33-specific CD8 T cells became nonfunctional
by day 30 and these mice were unable to control the viral
infection (Fig. 3 B). These results show that CD4 T cells
are essential to sustain effector functions of virus-specific
CD8 T cells during chronic infection.
Lack of viral clearance and persistence of unresponsive
GP33-specific CD8 T cells was also seen when 1/1 mice
were made CD4 deficient at the time of infection by in-
jecting them with a monoclonal antibody (GK1.5) to de-
plete CD4 T cells. 1/1 mice were injected with GK1.5 1 d
before and 3 d after LCMV-clone 13 or -t1b infection; this
treatment depleted .95% of the CD4 T cells but within 2
mo these mice had reconstituted their CD4 T cell com-
partment and contained normal levels of CD4 T cells (Fig.
4). However, GP33-specific CD8 T cells remained unre-
sponsive in these mice and there was no control of the vi-
rus infection (Fig. 4). It is particularly noteworthy that al-
though these mice had recovered their total number of
CD4 T cells, they did not contain any detectable LCMV-
specific CD4 T cells as measured by IFN-g and IL-2 pro-
duction (data not shown). These results show that the cru-
Figure 3. Kinetics of LCMV-specific CD8 T cell responses during
chronic infection. Splenocytes were prepared from either 1/1 or CD42/2
mice at various days after infection with LCMV-clone 13 (2 3 106 PFU,
i.v.). The total numbers of GP33- (h) and NP396- (s) specific CD8 T
cells were enumerated by staining with recombinant MHC H-2Db tetra-
mers, and IFN-g ELISPOT assays were performed to determine the func-
tional responsiveness of these cells (GP33–41, j; NP396–404, d). Serum
virus titers were also determined and are represented by the gray area.
Mean values are shown for two to four mice at each time point and the
limit of detection is represented by the dashed line. Standard deviations
were ,10%.2209 Zajac et al.
cial factor in maintaining CD8 T cell function during
chronic infection is not the total number of CD4 T cells
but the presence of antigen-specific helper cells. This find-
ing has obvious implications towards understanding the
regulation of HIV-specific CTL responses (16, 21).
Expression of Activation Markers and Turnover of Unrespon-
sive T Cells. We next asked whether these effector func-
tion–negative CD8 T cells express activation markers asso-
ciated with TCR signaling. These T cells were CD44hi
(Fig. 2 D) and also expressed low levels of CD62L (data not
shown). This phenotype, CD44hiCD62Llo, is characteristic
of activated/memory T cells and shows that these function-
ally “unresponsive” cells were antigen experienced (35,
38). However, neither of these two markers is indicative of
recent TCR stimulation. To examine this we checked ex-
pression of the very early T cell activation marker, CD69.
CD69 is rapidly upregulated after TCR-mediated signaling
but its expression is transient and dependent upon continu-
ous TCR activation (39–41). We found that the vast ma-
jority (z80%) of effector-function–negative GP33-specific
CD8 T cells were CD69hi (Fig. 5 A). This rather striking
result shows that these CD8 T cells are cognizant of the
continued presence of viral antigen and are receiving sig-
nals through their TCR but fail to elaborate downstream
effector functions. Even after treatment with PMA and
ionomycin, agents that activate protein kinase C and ele-
vate intracellular Ca21 levels, respectively (42, 43), GP33-
specific CD8 T cells in chronically infected CD42/2 mice
were unable to secrete IFN-g (Fig. 5 B). Since these virus-
specific CD8 T cells are maintained indefinitely in persis-
tently infected CD42/2 mice, we checked whether these
cells were turning over in vivo by BrdU incorporation (26,
32). Chronically infected CD42/2 and 1/1 mice (100 d
after infection) were given BrdU in the drinking water for
8 d and the percentage of cells that had replicated during
this period was determined by staining for BrdU incorpora-
tion in the nucleus, in combination with cell surface stains
(CD8 and tetramer) to identify the T cells. A representative
analysis is depicted in Fig. 5 C showing that the “unrespon-
sive” GP33-specific CD8 T cells do proliferate in vivo.
Discussion
The main point of this study is that virus-specific CD8 T
cells can persist indefinitely in chronically infected hosts.
These T cells express activation/memory markers (CD44hi
CD62Llo), are receiving signals through the TCR (CD69hi),
and can proliferate in vivo, but are unable to elaborate anti-
viral effector functions and thus fail to control the infec-
tion. Although T cell unresponsiveness (anergy) has been
extensively studied, cells of such a phenotype have not
been described previously (44–51). Moreover, the identifi-
cation of these activated but effector-function–negative T
cells reveals a new mechanism of silencing antiviral im-
mune responses during chronic infections. These CD8 T
cells seem to be engaged in a continual and ineffective ef-
fort much like the Greek king, Sisyphus, who was con-
demned forever to perform the fruitless task of pushing a
large stone up a hill only to see it roll down again. Our
studies show that these “Sisyphean” CD8 T cells are gener-
ated under conditions of chronic antigenic stimulus and are
especially prevalent when there is inadequate CD4 help.
Until now, deletion (exhaustion) of virus-specific CD8 T
cells has been considered as a more general mechanism of
tolerizing virus-specific immune responses during chronic
infections (13, 22–24). Our studies documenting persis-
tence of effector-function–negative antigen-specific CD8
T cells open new possibilities of therapeutic intervention
for enhancing CD8 T cell immunity in chronically infected
hosts. In addition, this study shows that within the same
persistently infected host different mechanisms can operate
to silence antiviral T cell responses; LCMV NP396-specific
cells were deleted, whereas GP33-specific cells were main-
tained indefinitely but without any detectable CTL or cyto-
kine secretion activity. Thus, strategies to enhance immune
function during chronic infection need to be tailored to-
wards individual epitopes.
In contrast to the strong correlation between CD4 help
and CD8 T cell effector function, we found an inverse cor-
relation between antigen persistence and responsiveness of
virus-specific CD8 T cells. Of the three LCMV strains used
in this study, clone 13 causes the most disseminated and
Figure 4. Chronic LCMV infec-
tion and CD8 T cell unresponsive-
ness ensue after transient loss of CD4
T cells. 1/1 mice were transiently
depleted of CD4 T cells by injection
with the anti-CD4 antibody, GK1.5,
1 d before and 3 d after infection
with LCMV-t1b. (A) Serum virus
titers were determined in 1/1 (d)
and GK1.5 treated (h) 1/1 mice at
various days after infection. (B) Re-
constitution of CD4 T cells in
GK1.5-treated mice was deter-
mined at 60 d after infection with
LCMV-t1b. Splenocytes were co-
stained for CD4 and the activation marker CD44. The percentage of CD41 cells are indicated in the upper quadrants. By this time point, both 1/1 and
GK1.5-treated mice contained comparable numbers of CD4 T cells. (C) Splenocytes from GK1.5-treated mice were prepared at 60 d after infection with
LCMV-t1b and both the total number (measured by tetramer staining) and the number of IFN-g–secreting (measured by ELISPOT) GP33- or NP396-
specific CD8 T cells were determined. Greater than 98.5% of GP33-specific T cells were unresponsive and NP396-specific T cells were not detectable. In
A and C the limit of detection is indicated by the dashed line. At least three mice were analyzed at each time point.2210 Silencing CD8 T Cells during Chronic Viral Infection
persistent infection with the highest antigen load, followed
by LCMV-t1b and then Armstrong, which only causes an
acute infection (Figs. 1 and 3 and reference 19). During the
course of acute LCMV Armstrong infection (which only
lasts about a week) and after viral clearance, all of the
GP33-specific CD8 T cells remained functional (Fig. 2 and
reference 26). In LCMV-t1b–infected 1/1 mice (viral
clearance in z2 mo), z60% of the GP33-specific CD8 T
cells were unresponsive during the first month after infec-
tion, but by day 90 all of these cells had become functional
(Fig. 2 and data not shown). However, in clone 13–
infected  1/1 mice, z80% of the GP33-specific T cells re-
mained unresponsive for an extended period. Thus, the
duration of exposure to viral antigen is a critical parameter
that influences T cell responsiveness. Clone 13 causes the
most prolonged infection and results in a pronounced
“functional deficit” within the GP33-specific CD8 T cell
population. Unlike LCMV-t1b infection, even after clone
13 infection has been controlled the GP33-specific T cells
do not rapidly regain their capacity to elicit antiviral effec-
tor functions. None of the LCMV strains used in this study
infect CD8 T cells; therefore, the unresponsiveness of
GP33-specific cells is not due to a direct effect of LCMV
replication within these cells. However, LCMV does repli-
cate within professional APCs and the presentation of viral
antigen by these cells can target them for destruction by vi-
rus-specific CTL (52, 53). Loss of professional APCs is least
apparent during Armstrong infection and most widespread
during clone 13 infection. Consequently, during systemic
LCMV infection professional APCs are destroyed and large
numbers of “nonprofessional” APCs may present viral anti-
gen. Such conditions are likely to favor the induction of
CD8 T cell unresponsiveness. Moreover, professional APCs
may be aberrantly activated in the absence of CD4 T cell
help and this may further promote the functional un-
responsiveness of CD8 T cells (54–57). Thus, a chronic an-
tigenic stimulus in the absence of adequate CD4 help
appears to be the worst possible scenario resulting in com-
plete loss of CD8 effector functions and uncontrolled virus
infection. Although such regulatory mechanisms are not
well suited to deal with chronic infections and tumors, they
may have evolved to prevent autoimmunity.
The degree of T cell activation is likely to be an impor-
tant parameter that determines whether CD8 T cells are
deleted or become functionally unresponsive (48). The ex-
tent of T cell activation can be influenced by the abun-
dance of antigen that is presented and also by the affinity of
the TCR for the given MHC–peptide complex. Virus-
infected cells will display both GP33 and NP396 epitopes
to responding T cells. One possibility is that different
amounts of GP33 and NP396 epitopes are presented in the
periphery of chronically infected adult mice (58, 59). Con-
sequently, GP33- and NP396-specific T cells may not be
similarly activated and therefore the fate of these T cells
could be differentially regulated. Alternatively, the on and
off rates of GP33- and NP396-specific TCRs may differ. In
this case even if both epitopes are present in similar con-
centrations on the infected cells, the responding T cells
may undergo different activation programs and conse-
quently succumb to different fates (i.e., deletion versus
nonresponsiveness). Interestingly, GP33-specific T cells are
not intrinsically resistant to deletion, and both GP33- and
NP396-specific T cells are undetectable by tetramer stain-
ing in congenitally infected LCMV carrier mice (data not
shown). These results suggest that GP33-specific CD8 T
cells can undergo deletion during central (thymic) toler-
ance.
Our findings are clearly relevant for understanding how
virus-specific CD8 T cell responses determine the outcome
of persistent viral infections. We have shown that virus-
Figure 5. GP33-specific CD8 T cells in chronically infected CD42/2
mice are activated and proliferate, but are refractive to stimulation with
PMA and ionomycin. (A) CD69 expression on freshly explanted spleno-
cytes from 1/1 and CD42/2 mice at 78 d after infection was assessed us-
ing flow cytometry. (B) IFN-g production by GP33-specific CD8 T cells
after PMA and ionomycin stimulation. Splenocytes were isolated from
1/1 and CD42/2 mice at 108 d after infection with LCMV-t1b. (C)
The in vivo proliferation of GP33-specific CD8 T cells in LCMV-t1b in-
fected 1/1 and CD42/2 mice (day 100 after infection) was assessed by in
vivo BrdU labeling. Mice were fed BrdU in their drinking water for a to-
tal of 8 d. All histograms show Db(GP33–41)-positive cells and the per-
centage of GP33-specific T cells within each region is indicated.2211 Zajac et al.
specific T cells that express activation markers, such as
CD44 and CD69, can be maintained in an unresponsive
state during chronic infections. Therefore, simply detecting
the physical presence of activated virus-specific CD8 T
cells, which turn over in vivo, does not necessarily mean
that these cells are operating to control the infection (60).
However, our data also demonstrate that not all virus-spe-
cific T cells need to be functionally competent in order to
resolve a chronic infection. For example, even though
NP396-specific T cells are deleted and only 10–20% of
GP33-specific T cells are functional, infection with LCMV
clone 13 is eventually resolved in 1/1 mice. This suggests
that for the control of persistent viral infections a threshold
of functional antiviral T cells needs to be maintained. The
number of functional antiviral CD8 T cells could fall below
this threshold if too many virus-specific CD8 T cells are ei-
ther deleted or become unresponsive, as occurs in the ab-
sence of CD4 T cell help. Such dampening of virus-specific
CD8 T cell responses would result in a more protracted or
even an uncontrollable infection.
The most striking finding of this study is that “activated”
but effector-function–negative virus-specific CD8 T cells
can persist indefinitely in chronically infected mice at re-
markably high frequencies (1–2% of total CD8 T cells). It is
likely that such effector-function–negative virus-specific
CD8 T cells will also be found in chronic viral infections of
humans. During HIV infection, CD8 CTLs play an impor-
tant role in controlling the viral burden and both deletion
and functional unresponsiveness may impair the efficacy of
these responses (16). Moreover, as progression to AIDS oc-
curs, the numbers of CD4 T cells decline, and Rosenburg
et al. (21) reported that weak HIV-specific CD4 T cell re-
sponses correlate with higher viral loads. This is consistent
with our data showing that CD4 T cells are required to
maintain the effector functions of virus-specific CD8 T
cells, and also suggests that if the number of functional vi-
rus-specific CD8 T cells falls below a threshold level, then
an uncontrollable chronic infection can ensue. Since CD8
T cells are potent mediators of viral clearance, it is impor-
tant to elucidate how to restore and sustain the effector
functions of virus-specific T cells. Antiviral therapies that
are designed to turn on the effector activity of preexisting
virus-specific CD8 T cells may be successful at both clear-
ing persistent infections and enhancing protective immu-
nity to reinfection.
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